On Wednesday, Following U.S. Stocks were among the “Top Gainers”: Express, (NYSE:EXPR), Capnia, (NASDAQ:CAPN), Warren Resources, (NASDAQ:WRES), Covenant Transportation Group, (NASDAQ:CVTI)

Express, (NYSE:EXPR), with shares inclined 3.48%, closed at $15.47.

Capnia, (NASDAQ:CAPN), with shares jumped 27.08%, settled at $7.04.

Warren Resources, (NASDAQ:WRES), with shares climbed 26.73%, and closed at $1.28.

Covenant Transportation Group, (NASDAQ:CVTI), surged 15.33%, and closed at $35.65, hitting new 52-week high of $35.94.

Latest NEWS regarding these Stocks are depicted underneath:

Express Inc. (NYSE:EXPR)

Express Inc. (EXPR), a specialty retail apparel chain operating about 640 stores, declared its financial results for the fourth quarter and full year 2014. These results cover the 13 and 52 week periods ended January 31, 2015 and compare to the 13 and 52 week periods ended February 1, 2014.

Fourth Quarter 2014 Operating Results:

• Net sales raised to $725.8 million from $715.9 million in the fourth quarter of 2014, an raise of 1%.
• Comparable sales during the quarter (counting e-commerce sales) reduced 2% against a comparable sales raise of 1% in last year’s fourth quarter. E-commerce sales rose 4% to $144.3 million.
• Merchandise margins grew by 70 basis points as the Corporation benefited from more targeted promotional activity contrast to the preceding year. Our buying and occupancy deleverage of 100 basis points, driven by higher rent and depreciation expense, resulted in a gross margin of 31.7% of net sales contrast to 32.0% in last year’s fourth quarter.
• Selling, general, and administrative (SG&A) expenses were $152.7 million as compared to $144.1 million in last year’s fourth quarter, primarily due to incremental marketing activities. As a percentage of net sales, SG&A expenses raised by 90 basis points to 21.0% contrast to 20.1% in last year’s fourth quarter.
• Operating revenue was $76.5 million, or 10.5% of net sales, contrast to $85.4 million, or 11.9% of net sales in the fourth quarter of 2013.
• Revenue tax expense was $27.7 million, at an effective tax rate of 39.8%, contrast to $31.8 million, at an effective tax rate of 39.9% in last year’s fourth quarter.
• Net revenue was $41.8 million, or $0.49 per diluted share. This compares to net revenue of $47.9 million, or $0.57 per diluted share, in the fourth quarter of 2013.
• Real estate activity for the fourth quarter of 2014 is detailed in Plan 4.

Express is a specialty apparel and accessories retailer of women’s and men’s merchandise, targeting the 20 to 30 year old customer. The Corporation has over 30 years of experience offering a distinct combination of fashion and quality for multiple lifestyle occasions at an attractive value addressing fashion needs across work, casual, jeanswear, and going-out occasions.

Capnia, Inc. (NASDAQ:CAPN)

Capnia, Inc. (CAPN), focused on the development of novel products based on its proprietary technologies for precision metering of gas flow, declared financial results for the fourth quarter and twelve months ended December 31, 2014.

Fourth Quarter 2014 and Recent Highlights:

Completion of Series B Warrant Transaction. In March 2015, Capnia accomplished a privately negotiated transaction with certain holders of Capnia’s Series B warrants who agreed to exercise their Series B warrants to purchase an aggregate of 589,510 shares of Capnia’s Ordinary Stock at an exercise price of $6.50 per share, resulting in gross proceeds to the Corporation of about $3.8 million. In connection with this exercise of Series B warrants, Capnia issued to each investor who exercised Series B warrants, new Series C warrants exercisable at $6.25 per share for the same number of shares of Ordinary Stock underlying the Series B warrants that were exercised. The cashless exercise feature that was contained in the Series B warrant that results in an increasing number of shares of Ordinary Stock issuable without consideration as the price of the Ordinary Stock decreases is not contained in the Series C warrants. Capnia intends to offer to all remaining holders of Series B warrants following a formal tender/registered exchange offer process, subject to certain limitations, the opportunity to exercise the Series B warrants held by them and receive Series C warrants on the same basis as in the private transaction.

Declared First U.S. Commercial Sales of CoSense. In February 2015, Capnia declared the first commercial sales of the Corporation’s CoSense ETCO Monitors and single-use sampling sets to leading healthcare institutions.

Presented CoSense Data at the 2014 American Society of Hematology. In December 2014, Capnia presented proof-of-concept data for the Corporation’s CoSense ETCO Monitor in patients with sickle cell anemia (SCA) at the 2014 American Society of Hematology Annual Meeting and Exposition in San Francisco. The Corporation believes CoSense has potential applications in the monitoring of a range of diseases involving hemolysis and altered bilirubin metabolism, and data from this study supports the potential of CoSense as a screening tool for neonates at risk for SCA.

Applied for Orphan Drug Designation in the U.S. for the Treatment of Trigeminal Neuralgia. In December 2014, Capnia presented an application to the U.S. Food and Drug Administration (FDA) requesting Orphan Drug Designation for its nasal CO2 technology for the treatment of TN. TN is a clinical condition characterized by debilitating pain in regions of the face innervated by one or more divisions of the trigeminal nerve.

Planned Partnership with Clinvest(R) to Develop Treatment for Cluster Headache. In January 2015, Capnia declared the execution of a Memorandum of Understanding (MOU), whereby the Corporation and Clinvest(R), a research organization dedicated to the advancement of medicine and health administration through clinical research, will collaborate to develop a therapeutic product for the treatment of cluster headache using Capnia’s proprietary nasal CO2technology. Under the terms of the MOU, Clinvest is predictable to conduct an investigator-sponsored clinical trial evaluating Capnia’s nasal CO2 on up to 50 patients with episodic cluster headaches. Capnia will provide the investigational product and logistical support for the trial, in addition to limited financial support.

Completion of Initial Public Offering. In November 2014, Capnia accomplished its IPO of 1,650,000 units, each unit comprising of one share of ordinary stock, one Series A warrant (exercisable into one share of ordinary stock) and one Series B warrant (exercisable into one share of ordinary stock) resulting in aggregate net proceeds of about $8.0 million. Proceeds from the IPO will be used to fund the ongoing commercial launch of CoSense, and related costs, and for working capital, capital expenditures, and other corporate purposes.

Capnia, Inc. develops and commercializes novel products based on its proprietary technologies for precision metering of gas flow. Capnia’s lead product is CoSense(R), which aids in the detection of hemolysis, a dangerous condition in which red blood cells degrade rapidly. CoSense, based on the Sensalyze(TM) Technology Platform, is a portable, non-invasive device that rapidly and accurately measures carbon monoxide in exhaled breath.

Warren Resources Inc. (NASDAQ:WRES)

Warren Resources Inc. (WRES), stated its fourth quarter and full-year 2014 financial and operating results.

Fourth Quarter of 2014 Results:

For the fourth quarter of 2014 Warren stated net revenue of $1.3 million, or $0.02 per basic and diluted share, contrast to net revenue of $3.7 million, or $0.05 per basic and diluted share for the fourth quarter of 2013.

The Corporation’s financial results in the fourth quarter of 2014 were influenced by $3.2 million of unrealized non-cash gains on commodity derivatives resulting from mark-to-market accounting, $0.7 million of net severance expense, and $0.1 million of additional attainment expenses pertaining to the Marcellus attainment.

Not including those items Warren had an adjusted net loss* for the fourth quarter of 2014 of $1.1 million, or a loss of $0.01 per diluted share, which compares to adjusted net revenue of $7.9 million, or $0.11 per share, in the fourth quarter of 2013.

Warren’s cash flow from operations in the fourth quarter of 2014 was $25.6 million, contrast to $21.2 million in the fourth quarter of 2013. The Corporation’s discretionary cash flow* (not including the influence of changes in working capital) in the fourth quarter of 2014 was $17.9 million, contrast to $18.2 million in the fourth quarter of 2013. EBITDA* for the fourth quarter of 2014 was $25.5 million, contrast to EBITDA of $14.9 million for the fourth quarter of 2013.

For the quarter ended December 31, 2014, Warren produced about 9.1 net billion cubic feet of gas equivalent (“Bcfe”), an average of 98.6 million cubic feet of gas equivalent per day (“MMcfe/d”), a 175% raise over the 3.3 net Bcfe produced in the fourth quarter of 2013. Warren produced about 293,000 net barrels of oil in the fourth quarter of 2014, an average of 3,183 barrels of oil per day (“BO/d”), contrast to about 292,000 net barrels of oil in the fourth quarter of 2013. Natural gas production totaled about 7.3 net billion cubic feet (“Bcf”) of natural gas in the fourth quarter of 2014, an average of 79.5 million cubic feet per day (“MMcf/d”), contrast to about 1.6 net Bcf of natural gas in the fourth quarter of 2013. The growth in total production is primarily attributable to the Corporation’s recently attaind Marcellus assets.

The average realized price per barrel of oil was $63.12 in the fourth quarter of 2014 contrast to $92.27 in the fourth quarter of 2013. The average realized price per thousand cubic feet (“Mcf”) of natural gas was $2.91 for the fourth quarter of 2014 contrast to $3.04 for the fourth quarter of 2013. These realized commodity prices exclude the effect of derivatives and hedging activities.

Warren’s oil and gas proceeds raised 25% to $39.8 million in the fourth quarter of 2014, contrast to $31.7 million in the fourth quarter of 2013. This primarily resulted from the raise in production volumes in the fourth quarter of 2014 contrast to the fourth quarter of 2013.

Total operating expenses and taxes were $41.5 million during the fourth quarter of 2014, contrast to $24.2 million during the fourth quarter of 2013, primarily due to raised operating activity and higher production volumes. On a per unit basis operating expenses reduced year-over-year in the fourth quarter of 2014 from the same period in 2013, with lease operating expenses and taxes (“LOE”) per Mcfe decreasing 37% to $1.80 and depletion, depreciation and amortization (“DD&A”) per Mcfe 31% lower to $2.18. The decrease in per unit operating expense reflects the influence of the low cost Marcellus assets and a decrease in the overall depletion rate.

General and Administrative (“G&A”) expenses were $4.5 million in the fourth quarter of 2014, contrast to $4.0 million in 2013, primarily driven by $0.7 million of net severance expenses related to the departure of the preceding CEO, partially offset by other G&A savings contrast to the fourth quarter of 2013. On a per unit basis G&A declined 59% in the fourth quarter 2014 from 2013, to $0.50/Mcfe. Non-cash stock-based compensation expense, a non-cash component of G&A, was a credit of $0.1 million for the fourth quarter of 2014, contrast to $0.6 million of expense in the same period in 2013.

The Corporation stated a net gain on derivative financial instruments of $6.4 million during the three months ended December 31, 2014, comprised of $3.2 million realized cash gains on commodity derivatives and $3.2 million of unrealized, non-cash gains on commodity derivatives.

Warren Resources, Inc., an independent energy corporation, is engaged in the exploration, development, and production of onshore crude oil and gas reserves. Warren’s activities are primarily focused on oil in the Wilmington field in the Los Angeles Basin in California, and natural gas in the Marcellus Shale in Pennsylvania and Washakie Basin in Wyoming.

Covenant Transportation Group, Inc. (NASDAQ:CVTI)

Covenant Transportation Group, Inc. (CVTI), declared its updated expectations regarding financial results for the first quarter of 2015.

Financial and Operating Results:

Chairman, President and Chief Executive Officer, David R. Parker, offered the following comments: “The Corporation has practiced year-over-year improvements in its operating results for the two months ended February 28, 2015, and these improvements have continued into March. For the first quarter to date, the Corporation has practiced the following:

• Demand has trended solidly above demand in the first quarter of 2014. For the two months ended February 28, 2015, freight proceed raised 11.6%, average freight proceed per total mile raised 5.1%, average miles per tractor per week raised 6.0%, and average freight proceed per tractor per week raised 11.4%, in each case contrast with the two months ended February 28, 2014. For the first few days of March, year-over-year average freight proceed per tractor per week has raised about consistent with the first two months of the quarter on a preliminary basis and before month-end adjustments.
• Average seated truck count has raised sequentially by about 70 trucks for the two months ended February 28, 2015, contrast with our average seated truck count for fourth quarter of 2014. The average number of tractors in the fleet was 2,704 for the two months ended February 28, 2015 as compared to 2,663 for the two months ended February 28, 2014.

Covenant Transportation Group, Inc., together with its auxiliaries, offers truckload transportation and brokerage services in the continental United States. The merged group comprises operations from Covenant Transport and Covenant Transport Solutions of Chattanooga, Tennessee; Southern Refrigerated Transport of Texarkana, Arkansas; and Star Transportation of Nashville, Tennessee.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.